Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 38: 2082-2086, 1992;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hartter, S.
Right arrow Articles by Hiemke, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hartter, S.
Right arrow Articles by Hiemke, C.

Clinical Chemistry, Vol 38, 2082-2086, Copyright © 1992 by American Association for Clinical Chemistry

Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography

S Hartter, H Wetzel and C Hiemke
Psychiatrische Klinik, Universitat Mainz, FRG.

A column-switching system with high-performance liquid-chromatographic separation and ultraviolet detection is described for automated determination of fluvoxamine in human plasma or serum. Samples were injected and the drug was retained in a clean-up column [20 x 4.6 mm (i.d.)] filled with C8 reversed-phase material (10-micron particles). After unwanted material was washed out, the drug was eluted and separated with an analytical chromatography column, 4.6 x 250 mm (i.d.), filled with Nucleosil 100 CN (5-micron particles) with an acetonitrile:methanol:0.01 mol/L phosphate buffer eluent (188:578:235 by vol) at a flow rate of 1.5 mL/min for < 20 min and detected by spectrometry at 214 nm. With oxaprotiline as internal standard, fluvoxamine could be easily quantified, and it was well separated from endogenous plasma constituents and various psychoactive drugs. The detection limit was 10 micrograms/L (31.6 nmol/L), the analytical recoveries were 97-100%, and the relationship between drug concentration and detector response was linear from 0 to 1000 micrograms/L (3160 nmol/L). The automated method is suitable for therapeutic monitoring of fluvoxamine in the treatment of psychiatric patients.


The following articles in journals at HighWire Press have cited this article:


Home page
 Arch Gen PsychiatryHome page
H. Jahn, M. Schick, F. Kiefer, M. Kellner, A. Yassouridis, and K. Wiedemann
Metyrapone as Additive Treatment in Major Depression: A Double-blind and Placebo-Controlled Trial
Arch Gen Psychiatry, December 1, 2004; 61(12): 1235 - 1244.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
M. Grozinger, S. Hartter, X. Wang, J. Roschke, C. Hiemke, and D.-M. Rose
Fluvoxamine Strongly Inhibits Melatonin Metabolism in a Patient With Low-Amplitude Melatonin Profile
Arch Gen Psychiatry, August 1, 2000; 57(8): 812 - 813.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American Association for Clinical Chemistry.